FOR US RESIDENTS ONLY

HCP Site
Young woman EPS representative
Young woman EPS rep

You have support for access and cost

As part of the LEQEMBI Companion program, EPS offers information and
resources to help you access LEQEMBI. Whether you’re starting therapy or continuing with
maintenance treatment, you have support.

We can help with:

  • Check Understanding insurance coverage and potential out-of-pocket costs
  • Check Identifying financial support programs, including the LEQEMBI Copay Assistance Program for eligible patients
  • Check Locating an infusion center, or Specialty Pharmacy, if you or your healthcare provider need assistance
Light bulb callout icon

How do I enroll in the LEQEMBI Companion program?

Enrolling in the LEQEMBI Companion program is simple, but both patients
and healthcare providers need to participate. Talk to your healthcare provider
about enrolling in the LEQEMBI Companion program during your next visit.

Questions? Call 1-833-453-7362 (1-833-4-LEQEMBI) for support.

Step 1:

Your healthcare provider will select program offerings for which you will be evaluated, and will fill in
additional information required by them.

They will ask you to complete all patient sections of the form, including required signatures for the
programs selected. Your healthcare provider may assist you in completing your portion of the form.

You may complete the enrollment form in person with your healthcare provider, or you may enroll digitally by visiting LEQEMBIEnrollment.com

If you or your healthcare provider needs additional assistance with enrollment, you may call
the LEQEMBI Companion program at 1-833-453-7362 (1-833-4-LEQEMBI) to speak with a
Patient Navigator.

Step 2:

Your healthcare provider will fax the completed enrollment form to the LEQEMBI Companion program
at 1-833-770-7017.

What happens after my healthcare provider and I enroll?

Once all required information and signatures are provided by you and your healthcare provider, the
LEQEMBI Companion program will reach out to you with next steps, and to welcome you to the program.

Download the enrollment form

Need access to forms or materials?

Certain enrollment forms and important resources are available here:

LEQEMBI Companion Program Enrollment Form Health Insurance Brochure Medicare Open
Enrollment Guide

Have questions?

Call the LEQEMBI Companion program at 1-833-453-7362 (1-833-4-LEQEMBI).

Advocacy organizations supporting people
affected by Alzheimer's disease

The following patient advocacy organizations might provide additional information or assistance, including educational tools, counseling, and support groups.*

Alzheimer’s Association patient support organization
AFA patient support organization
Being Patient support organization
Us Against Alzheimer’s patient support organization

*The organizations listed are independent from Eisai. Eisai does not influence or control the operations or eligibility criteria for these independent programs. This information is provided for informational purposes only.

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

IMPORTANT SAFETY INFORMATION

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

EXPAND COLLAPSE

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

IMPORTANT SAFETY
INFORMATION

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects, including:

ARIA (Amyloid-Related Imaging Abnormalities). ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

  • ARIA commonly shows up as temporary swelling in areas of the brain that usually goes away over time

  • Small spots of bleeding in or on the surface of the brain can occur 

  • Less often, larger areas of bleeding in the brain can occur 

  • Most people with ARIA don’t have any symptoms. However, some people may notice

    – headache

    – confusion that
    gets worse

    – dizziness

    – vision changes

    – nausea

    – difficulty walking

    – seizures

    – difficulty speaking

    – muscle weakness

  • Some people have a gene called ApoE4 that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have
    this gene

  • You may be at a higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving LEQEMBI. Talk to your healthcare provider to see if any of the medicines you’re taking increase this risk

  • Your healthcare provider will check for ARIA with MRI (magnetic resonance imaging) scans before you start LEQEMBI and
    during treatment

  • You should carry information that says you are receiving LEQEMBI, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms

Call your healthcare
provider or go to the nearest hospital emergency room
right away if you have any of the symptoms listed above.

Serious allergic reactions:

Do not receive LEQEMBI if you have serious allergic reactions to LEQEMBI, LEQEMBI IQLIK, or any of the ingredients.

  • Tell your healthcare provider if you notice any symptoms during or after a LEQEMBI infusion, including:

    – swelling of the face, lips, mouth, or tongue

    – itchy bumps on the skin, also known as hives

    – difficulty breathing

Infusion-related reactions:

  • Infusion-related reactions can occur during or after completion with LEQEMBI injection into a vein (intravenously), which can be serious. Tell your healthcare provider right away if you notice any of these symptoms:

    – fever

    – flu-like symptoms (chills, body aches, feeling shaky, joint pain)

    – nausea and/or vomiting

    – dizziness or lightheadedness

    – fast or slow heart rate, or feeling like your chest is pounding

    – difficulty breathing or shortness of breath

    – changes in blood pressure

  • If you have an infusion-related reaction, your healthcare provider may give you medicines before your next infusion to lower the chance of having a reaction

Injection-related reactions:

  • Injection-related reactions may occur with LEQEMBI injection under the skin (subcutaneous injection with LEQEMBI IQLIK). Tell your healthcare provider if you notice any of these symptoms during or after an injection:

    – redness, swelling, heat, pain, itching, rash, bruising, and blood collection under the skin at the injection site

    – headache, fatigue, or fever may also be observed after an injection

The most common side effects of LEQEMBI include infusion-related reactions, ARIA, and headaches.

These are not all the possible side effects of LEQEMBI. Call your doctor for more information and medical advice about side effects. You may report side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Before receiving LEQEMBI, tell your healthcare provider about:

  • All your medical conditions, including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if LEQEMBI could harm your unborn or breastfeeding baby

  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin) 

LEQEMBI (lecanemab-irmb) is available as:

  • Intravenous infusion: 100 mg/mL

  • Subcutaneous injection: 200 mg/mL

Please see Medication Guide with Instructions for Use and full Prescribing Information, including Boxed WARNING, for LEQEMBI.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries. This Website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved ones’, personal medical needs. Individual responses to treatment may vary.